KEGG   DRUG: Lumasiran sodium
Entry
D11926                      Drug                                   

Name
Lumasiran sodium;
Oxlumo (TN)
Product
Formula
C530H669F10N173O320P43S6Na43
Exact mass
17277.3877
Mol weight
17285.7558
Remark
ATC code: A16AX18
Chemical structure group: DG03131
Product (DG03131): D11926<US>
Efficacy
Oxalate production reduction
  Disease
Primary hyperoxaluria type 1 [DS:H00117]
Comment
RNA interference (RNAi) drug
Target
HAO1 [HSA:54363] [KO:K11517] (mRNA)
  Pathway
hsa00630  Glyoxylate and dicarboxylate metabolism
hsa04146  Peroxisome
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 A ALIMENTARY TRACT AND METABOLISM
  A16 OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
   A16A OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
    A16AX Various alimentary tract and metabolism products
     A16AX18 Lumasiran
      D11926  Lumasiran sodium <US>
Target-based classification of drugs [BR:br08310]
 Enzymes
  Oxidoreductases (EC1)
   Oxidases
    HAO1
     D11926  Lumasiran sodium <US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D11926
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D11926
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D11926
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system